Vanda Pharmaceuticals (VNDA) surges 20% in premarket trading after Cycle Pharmaceuticals reaffirms $8/share all cash offer in ...

Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker ...

UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals in a deal that values the US ...

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s ...

Cycle’s second unsuccessful takeover bid comes on the heels of the FDA denying approval for Vanda’s tradipitant, which was ...

Cycle Pharmaceuticals reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals ...

Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to ...

Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is ...

Vanda Pharmaceuticals rejected a second acquisition proposal from Cycle Group Holdings, saying terms are economically identical to a previously rejected indication of interest and that it ...

Vanda Pharmaceuticals Inc. (VNDA) confirmed on Monday that it received a second unsolicited, non-binding proposal from Cycle Group ...

On Monday, Vanda Pharmaceuticals Inc. (VNDA) stock saw a modest uptick, ending the day at $4.81 which represents a slight increase of $0.37 or 8.33% from the prior close of $4.44. The stock opened at ...